Pharmaceutical Technology on MSN9d
Opko and Entera focus on oral care for obesity and metabolic disorders
Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...
Contract Pharma9d
OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1
OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...
Nasdaq10d
OPKO Health, Entera Bio Collaborate To Develop Oral Dual GLP-1/Glucagon Therapy For Obesity
The program combines OPKO's long-acting oxyntomodulin analog or OPK-88006 with Entera's proprietary N-Tab technology, and promising pharmacodynamic data has already been reported. The goal of the ...
MetaVia Inc.: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 ...